I recently finished listening to their March 31st conference call,and It was a very Informative and upbeat call. I recommend that anyone Interested In this company take a listen. In the first half of 2011 look for these developments as possible catalysts for the stock. The company plans to submit to medicare for re- Inbursement consideration for wound care. They plan to submit FDA 510K applications for an enhanced Autologel PRP device,and for a new Angel Indication. They want to complete the Angel and activeAT manufacturing transition and transfer CE marks. And finally, they want to collect clinical data and publish two clinical articles. More to come :)